Phospho-TNNI3 (S43) Antibody

What is TNNI3 and what is its functional role in cardiac physiology?

TNNI3 (cardiac troponin I) functions as the inhibitory subunit of the troponin complex in cardiac muscle tissue. It plays a critical role in regulating calcium-sensitive striated muscle actomyosin ATPase activity, essentially serving as a molecular switch that controls the interaction between actin and myosin in response to calcium . In the cardiac troponin complex, TNNI3 works alongside troponin C (TnC) and troponin T (TnT) to regulate cardiac muscle contraction.

The protein has several functional domains:

• It contains binding sites for actin, tropomyosin, and other troponin subunits

• Its inhibitory region (residues 128-147) and switch region (residues 147-163) are particularly important for function

• Multiple phosphorylation sites that regulate its activity under various physiological conditions

TNNI3 is expressed primarily in cardiac tissue, with the canonical human protein consisting of 210 amino acid residues and a molecular weight of approximately 24 kDa .

What is the significance of S43 phosphorylation on TNNI3?

Phosphorylation at S43 represents one of several regulatory mechanisms that modulate cardiac troponin I function. According to research findings, phosphorylation of TNNI3 at sites S43 and S45 by protein kinase C (PKC) has a significant functional effect, slowing the myosin ATPase rate and increasing the calcium sensitivity of troponin I . This is in direct contrast to phosphorylation at other sites such as S23/S24, which decreases calcium sensitivity and promotes faster relaxation.

The specific molecular consequences of S43 phosphorylation include:

• Modulation of protein-protein interactions within the troponin complex

• Alteration of calcium sensitivity of the myofilament

• Impact on the contractile properties of cardiac muscle

While phosphorylation at S43 has been studied less extensively than the S23/S24 sites, research indicates it plays an important role in the response to specific physiological stimuli and potentially in pathological cardiac conditions .

What are the recommended applications for Phospho-TNNI3 (S43) antibodies?

Based on the search results, Phospho-TNNI3 (S43) antibodies are validated and recommended for several laboratory applications:

When using these antibodies, researchers should note:

• The antibodies have been specifically validated for detecting phosphorylation at the S43 site

• They typically show a band at approximately 24-30 kDa in Western blots

• Proper controls, including phosphopeptide blocking experiments, are recommended to confirm specificity

What is the species reactivity of commercially available Phospho-TNNI3 (S43) antibodies?

Most commercially available Phospho-TNNI3 (S43) antibodies demonstrate cross-reactivity with multiple species. According to the product information from several manufacturers:

The cross-reactivity is due to the high conservation of the amino acid sequence surrounding the S43 phosphorylation site across mammalian species. This conservation allows researchers to use the same antibody across multiple experimental models.

How does S43 phosphorylation mechanistically differ from other phosphorylation sites on TNNI3?

TNNI3 contains multiple phosphorylation sites that regulate cardiac function differently. Their comparative effects reveal distinct regulatory mechanisms:

Research by Abbott et al. used NMR spectroscopy to determine that S41/S43 phosphorylation of the cRp region (residues 34-71) had minimal disruption in the interaction between cRp and calcium-bound troponin C . This contrasts significantly with phosphorylation of T142 or S149, which substantially reduced binding affinity to different domains of troponin C.

The differential effects of these phosphorylation sites highlight how post-translational modifications create a complex regulatory network that fine-tunes cardiac contractility under varying physiological conditions.

What methodological considerations should researchers account for when using Phospho-TNNI3 (S43) antibodies in different experimental setups?

When utilizing Phospho-TNNI3 (S43) antibodies, researchers should consider several methodological factors to ensure reliable results:

For Western Blot:

• Sample preparation is critical—phosphorylation can be lost during extraction; use phosphatase inhibitors

• Proper controls including non-phosphorylated samples and phospho-blocking peptides are essential

• Predicted band size is ~24 kDa, but observed band size may be ~30 kDa due to post-translational modifications

• Recommended dilution ranges from 1:500-1:2000

For Immunohistochemistry:

• Fixation method can affect phospho-epitope accessibility

• Antigen retrieval steps may be necessary but should be optimized to prevent dephosphorylation

• Dilution range of 1:100-1:300 is typically recommended

• Background staining should be carefully controlled with appropriate blocking reagents

For ELISA:

• Much higher dilutions (1:40000) may be required due to the sensitivity of the assay

• Consider using cell-based ELISA formats for measuring relative phosphorylation levels in intact cells

• Colorimetric detection can be combined with crystal violet staining for cell number normalization

Storage and Handling:

• Store antibodies at -20°C for long-term or 4°C for short-term/frequent use

• Avoid repeated freeze-thaw cycles which can degrade antibody performance

• Liquid formulations typically contain 50% glycerol, 0.5% BSA and 0.02% sodium azide

How can researchers validate the specificity of Phospho-TNNI3 (S43) antibodies in their experimental systems?

Validating antibody specificity is crucial for reliable research outcomes. For Phospho-TNNI3 (S43) antibodies, several validation strategies are recommended:

• Phospho-blocking peptide experiments

  • Compare antibody reactivity with and without pre-incubation with the phosphorylated peptide used as immunogen

  • A specific antibody will show significantly reduced or eliminated signal when blocked with its cognate phosphopeptide

• Phosphatase treatment controls

  • Treat duplicate samples with phosphatase enzymes to remove phosphorylation

  • Specific phospho-antibodies should show decreased or absent signal in treated samples

• Stimulation experiments

  • Treat cells with activators or inhibitors of kinases known to phosphorylate S43 (e.g., PKC activators)

  • Observe expected changes in signal intensity corresponding to treatment

• Genetic controls

  • Use TNNI3 knockout/knockdown models as negative controls

  • Employ site-directed mutagenesis (S43A) to create phospho-null controls

• Multiple detection methods

  • Confirm findings using alternative techniques (e.g., Mass spectrometry)

  • Use different antibody clones that recognize the same phospho-epitope

A comprehensive validation approach combining several of these methods provides the strongest evidence for antibody specificity.

When conducting structure-function studies using Phospho-TNNI3 (S43) antibodies, researchers should consider several factors for proper data interpretation:

• Structural context of S43 phosphorylation:

  • S43 is located in the N-terminal region of TNNI3 (residues 34-71)

  • Unlike other phosphorylation sites that dramatically affect troponin C binding, S41/S43 phosphorylation has minimal disruption in protein-protein interactions with calcium-bound troponin C

  • This suggests S43 phosphorylation may have more subtle regulatory effects or influence interactions with other binding partners

• Comparative analysis with other phosphorylation sites:

  • Analyze S43 phosphorylation in context with other sites (S23/S24, T142, S149)

  • Consider the combined effects of multiple phosphorylation sites, as cardiac regulation often involves patterns of phosphorylation rather than single sites

• Correlation with functional assays:

  • Link phosphorylation detection to functional measurements (e.g., calcium sensitivity, ATPase activity)

  • The increased calcium sensitivity associated with PKC-mediated phosphorylation at S43/S45 should correlate with specific contractile properties

• Mutation and phosphorylation interplay:

  • FHC mutations near phosphorylation sites can enhance or suppress phosphorylation effects

  • For example, while R144G enhances the effect of T142 phosphorylation, R161W suppresses the effect of S149 phosphorylation

  • Consider how nearby mutations might affect S43 phosphorylation functionality

• Species differences:

  • While the S43 region is highly conserved, subtle sequence differences between species may affect antibody reactivity or phosphorylation consequences

  • Interpret cross-species comparisons with appropriate caution

By considering these factors, researchers can more accurately interpret the structural and functional significance of S43 phosphorylation in their experimental systems.

What are the emerging applications of Phospho-TNNI3 (S43) antibodies in non-cardiac research?

While TNNI3 is primarily associated with cardiac research, emerging evidence suggests broader applications for Phospho-TNNI3 (S43) antibodies:

Particularly notable is the recent discovery of TNNI3 expression in ovarian tissue. Research has shown that "pregranulosa cells upregulate Tnni3 expression upon cell cycle resumption, in a Cdkn1b/p27kip1 responsive manner, during primordial follicle activation" . TNNI3 staining was detected in granulosa cells at postnatal day 4 and 7, but not at embryonic day 18.5, suggesting a developmental role beyond cardiac tissue .

These findings open new research directions where Phospho-TNNI3 (S43) antibodies may provide insights into cellular processes beyond cardiac contractility.

How can researchers optimize Phospho-TNNI3 (S43) antibody use in multiplexed detection systems?

Optimizing Phospho-TNNI3 (S43) antibodies for multiplexed detection requires careful consideration of several technical aspects:

• Antibody compatibility:

  • When combining antibodies for simultaneous detection, ensure compatibility of host species to avoid cross-reactivity

  • Consider using antibodies from different host species or isotypes when detecting multiple phosphorylation sites

• Sequential staining protocols:

  • For IHC/IF applications, sequential staining may be necessary when using multiple antibodies of the same species

  • Implement proper blocking steps between sequential applications

• Fluorophore selection for immunofluorescence:

  • Choose fluorophores with minimal spectral overlap

  • Account for relative abundance of different phosphorylation sites when selecting fluorophore brightness

• Cell-based ELISA optimization:

  • For the cell-based colorimetric ELISA approach, calibrate primary antibody concentrations carefully

  • As noted in the ImmunoWay protocol: "Based on the experiment design, primary antibody incubation can be performed with different anti-total protein antibody"

• Control strategy:

  • Include phospho-specific controls for each target in the multiplex panel

  • Consider using recombinant standards with known phosphorylation states

• Quantification methods:

  • Establish appropriate normalization strategies when comparing multiple phosphorylation sites

  • Use total TNNI3 antibodies alongside phospho-specific antibodies for accurate phosphorylation ratio calculations

By optimizing these parameters, researchers can effectively implement multiplexed detection systems to simultaneously monitor multiple phosphorylation sites on TNNI3 or combine TNNI3 phosphorylation detection with other cardiac markers.

What are common pitfalls when working with Phospho-TNNI3 (S43) antibodies and how can they be addressed?

Researchers may encounter several challenges when working with Phospho-TNNI3 (S43) antibodies. Here are common issues and their solutions:

For Western blot applications, the predicted band size for TNNI3 is approximately 24 kDa, but the observed band may appear at around 30 kDa . This discrepancy should not necessarily be considered problematic, as it can result from post-translational modifications or gel migration differences.

How should researchers monitor and maintain antibody quality over time?

To ensure consistent experimental results, researchers should implement quality control measures for Phospho-TNNI3 (S43) antibodies:

• Initial validation:

  • Perform comprehensive validation using methods described in section 2.3

  • Document baseline performance metrics for future comparison

• Storage and handling:

  • Store according to manufacturer recommendations: -20°C for long-term, 4°C for short-term use

  • Aliquot antibodies to minimize freeze-thaw cycles

  • As noted by Boster Bio: "Avoid repeated freeze-thaw cycles"

• Regular performance checks:

  • Include positive controls in each experiment

  • Periodically test with phosphatase-treated negative controls

  • Monitor signal-to-noise ratio over time

• Lot-to-lot variation:

  • When receiving a new lot, run side-by-side comparison with previous lot

  • Document lot numbers and any observed performance differences

  • Consider purchasing larger quantities of a single lot for long-term projects

• Documentation and standardization:

  • Maintain detailed records of antibody performance

  • Standardize protocols to minimize variation

  • Consider creating internal reference standards

• Alternative detection methods:

  • Periodically confirm key findings with orthogonal methods

  • Consider using multiple antibody clones targeting the same phosphorylation site

By implementing these quality control measures, researchers can maintain consistent antibody performance and ensure reliability of their experimental data over time.